FOXO:NYE-FOXO Technologies Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 0.1981

Change

0.00 (-0.20)%

Market Cap

N/A

Volume

0.25M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-1.12 (-1.62%)

USD 10.78B
DOCS Doximity Inc

+0.66 (+1.58%)

USD 7.70B
WEAV Weave Communications Inc

-0.11 (-0.91%)

USD 0.86B
AMWL American Well Corp

-0.34 (-3.47%)

USD 0.15B
MPLN MultiPlan Corporation

+0.65 (+9.00%)

USD 0.12B
OWLT Owlet Inc

+0.23 (+5.30%)

USD 0.07B
PHR Phreesia Inc

-0.25 (-1.11%)

N/A
VEEV Veeva Systems Inc Class A

+4.30 (+2.10%)

N/A
EVH Evolent Health Inc

+1.24 (+4.48%)

N/A
TDOC Teladoc Inc

-0.06 (-0.71%)

N/A

ETFs Containing FOXO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.04% 40% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.04% 40% F 4% F
Trailing 12 Months  
Capital Gain -81.69% 20% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.69% 20% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -44.53% 10% F N/A F
Dividend Return -44.53% 10% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.74% 70% C- 20% F
Risk Adjusted Return -97.35% 20% F 1% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector